Background and objectives Idiopathic collapsing FSGS has historically been associated with poor renal outcomes. Minimal clinical data exist on the efficacy of immunosuppressive therapy. Our study sought to provide a comprehensive description of renal survival in patients with collapsing and not otherwise specified FSGS after controlling for factors affecting renal prognosis. Design, setting, participants, & measurements We performed a retrospective analysis of an inception cohort study of patients diagnosed between 1989 and 2012. All potential patients with collapsing FSGS fulfilling the inclusion criteria were identified and compared with patients with not otherwise specified FSGS (approximately 1:2 ratio) on the basis of biopsy report and record availability. Time to ESRD was analyzed using Cox proportional hazards models. Results In total, 187 patients were studied (61 collapsing and 126 not otherwise specified), with a mean follow-up of 96 months. At baseline, patients with collapsing FSGS had higher median proteinuria (12.2 [5.6–14.8] versus 4.4 [2.3–8.1] g/d, respectively; P<0.001), lower median albuminemia (2.4 [1.9–3.0] versus 2.9 [1.8–3.7] g/dl, respectively; P=0.12), and lower median eGFR (48 [26–73] versus 60 [42–92] ml/min per 1.73 m2, respectively; P=0.01) than patients with not otherwise specified FSGS. The proportion of patients with remission of proteinuria was similar in patients with collapsing FSGS and patients with not otherwise specified FSGS (65.7% [23 of 35] versus 63.2% [72 of 114], respectively; P=0.84). The overall renal outcome (ESRD defined as eGFR<15 ml/min per 1.73 m2, dialysis, or transplantation) of patients with collapsing FSGS was not poorer than that of patients with not otherwise specified FSGS in multivariate analyses after adjusting for baseline characteristics and immuno-therapy (hazard ratio, 1.78; 95% confidence interval, 0.92 to 3.45). Conclusions Compared with not otherwise specified FSGS, idiopathic collapsing FSGS presented with more severe nephrotic syndrome and lower eGFR but had a similar renal survival after controlling for exposure to immunosuppressive treatment. These results highlight the importance of early diagnosis and institution of immunosuppressive therapy in patients with collapsing FSGS.
|Original language||English (US)|
|Number of pages||8|
|Journal||Clinical Journal of the American Society of Nephrology|
|State||Published - Oct 7 2016|
Bibliographical noteFunding Information:
L.-P.L. received salary support from the Hôpital Maisonneuve-Rosemont Scholarship of Improvement Program, the Société Québécoise de Néphrologie, and the Department of Medicine, Université de Montréal. V.K.D was supported by NephCure Foundation Nephrotic Syndrome Study Network Career Development Award grant U-54-DK-083912.
© 2016 by the American Society of Nephrology.
- Focal segmental glomerulosclerosis
- Follow-up studies
- Glomerular filtration rate
- Kidney failure, chronic
- Nephrotic syndrome
- Proportional hazards models
- Renal dialysis